A Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects With Chronic Pseudomonas Aeruginosa (PsA) Pulmonary Infection
Latest Information Update: 21 Nov 2024
At a glance
- Drugs BX 004 (Primary)
- Indications Pseudomonal infections
- Focus Adverse reactions; Proof of concept
- Sponsors BiomX
Most Recent Events
- 14 Nov 2024 According to a BiomX media release, Results from this study continue to receive positive feedback at major scientific conferences.
- 18 Sep 2024 Results published in the BiomX Media Release.
- 18 Sep 2024 According to a BiomX media release, the Company will present data from Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections in two sessions at the North American Cystic Fibrosis Conference in Boston.